Preview

Кардиология

Расширенный поиск

Тактика ведения пациентов с фибрилляцией предсердий и малыми кровотечениями в условиях терапии прямыми пероральными антикоагулянтами

https://doi.org/10.18087/cardio.2021.12.n1872

Полный текст:

Аннотация

Рекомендованной тактикой профилактики тромбоэмболических осложнений при фибрилляции предсердий (ФП) является использование пероральных антикоагулянтов (ПОАК). Препаратами выбора для предотвращения инсульта у подавляющего большинства пациентов с ФП, за исключением некоторых клапанных пороков, служат прямые пероральные антикоагулянты (ППОАК). Вне зависимости от класса препарата все антикоагулянты, даже при использовании правильной дозы, увеличивают риск развития кровотечений. Однако наличие малых кровотечений не служит абсолютным показанием к отмене ППОАК. В обзоре представлена тактика ведения пациентов при малых кровотечениях на фоне приема ППОАК.

Об авторах

Ю. Н. Беленков
ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский Университет), Москва
Россия

Директор Клиники госпитальной терапии им. А.А. Остроумова, заведующий кафедрой госпитальной терапии №1  Института клинической медицины им. Н.В. Склифосовского, член-корр. РАН, академик РАМН, проф., д.м.н.



Л. В. Попова
ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский Университет), Москва
Россия

Конфликт интересов:

к.м.н., доцент кафедры госпитальной терапии №1  Института клинической медицины им. Н.В. Склифосовского



И. С. Ильгисонис
ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский Университет), Москва
Россия

Профессор кафедры госпитальной терапии №1 Института клинической медицины им. Н.В. Склифосовского, к.м.н., врач-кардиолог, SPIN 6806-9299



Список литературы

1. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. The American Journal of Cardiology. 2013;112(8):1142–7. DOI: 10.1016/j.amjcard.2013.05.063

2. Krijthe BP, Kunst A, Benjamin EJ, Lip GYH, Franco OH, Hofman A et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. European Heart Journal. 2013;34(35):2746–51. DOI: 10.1093/eurheartj/eht280

3. Колбин А.С., Мосикян А.А., Татарский Б.А. Социально-экономическое бремя фибрилляции предсердий в России: динами-ка за 7 лет (2010-2017 годы). Вестник аритмологии. 2018;92:42-8. DOI: 10.25760/VA2018-92-42-48

4. Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948. DOI: 10.1016/j.cjca.2020.09.001

5. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW et al. Heart Disease and Stroke Statistics–2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254–743. DOI: 10.1161/CIR.0000000000000950

6. Strickberger SA, Ip J, Saksena S, Curry K, Bahnson TD, Ziegler PD. Relationship between atrial tachyarrhythmias and symptoms. Heart Rhythm. 2005;2(2):125–31. DOI: 10.1016/j.hrthm.2004.10.042

7. Christow S, Seidl K, Diener H-C, Huisman Mv, Lip G, Rauch-Kroenert U et al. 1669Increased rate of previous stroke in asymptomatic/ minimally symptomatic versus symptomatic patients with newly detected atrial fibrillation in western Europe results from the GLORIAAF registry. EP Europace. 2017;19(Suppl 3):iii355–6. DOI: 10.1093/ehjci/eux159.005

8. Арутюнов Г.П., Фомин B. В., Тарловская Е.И., Арутюнов А.Г., Аляви А.Л., Вышлов Е.В. и др. Резолюция Евразийской Ассоциации терапевтов. Алгоритм оценки и модификации факторов риска небольших кровотечений у пациентов с фибрилляцией предсердий, получающих терапию ППОАК. 2019. Доступно на: https://euat.ru/upload/recommendation/1566466669.pdf

9. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2020;42(5):373–498. DOI: 10.1093/eurheartj/ehaa612

10. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51. DOI: 10.1161/CIR.0000000000000665

11. Chiang C-E, Okumura K, Zhang S, Chao T-F, Siu C-W, Wei Lim T et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. Journal of Arrhythmia. 2017;33(4):345–67. DOI: 10.1016/j.joa.2017.05.004

12. Gamra H, Murin J, Chiang C-E, Naditch-Brûlé L, Brette S, Steg PG et al. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Archives of Cardiovascular Diseases. 2014;107(2):77–87. DOI: 10.1016/j.acvd.2014.01.001

13. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ et al. Detection of Atrial Fibrillation After Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. Stroke. 2014;45(2):520–6. DOI: 10.1161/STROKEAHA.113.003433

14. Alamneh EA, Chalmers L, Bereznicki LR. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices? American Journal of Cardiovascular Drugs. 2016;16(3):183–200. DOI: 10.1007/s40256-016-0161-8

15. Reiffel JA. Atrial Fibrillation and Stroke: Epidemiology. The American Journal of Medicine. 2014;127(4):e15–6. DOI: 10.1016/j.amjmed.2013.06.002

16. Xian Y, O’Brien EC, Liang L, Xu H, Schwamm LH, Fonarow GC et al. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA. 2017;317(10):1057–67. DOI: 10.1001/jama.2017.1371

17. Arts DL, Visscher S, Opstelten W, Korevaar JC, Abu-Hanna A, van Weert HCPM. Frequency and Risk Factors for Underand OverTreatment in Stroke Prevention for Patients with Non-Valvular Atrial Fibrillation in General Practice. PLoS ONE. 2013;8(7):e67806. DOI: 10.1371/journal.pone.0067806

18. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. The American Journal of Medicine. 2010;123(7):638-645.e4. DOI: 10.1016/j.amjmed.2009.11.025

19. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials. The Lancet. 2014;383(9921):955–62. DOI: 10.1016/S0140-6736(13)62343-0

20. Marzec LN, Wang J, Shah ND, Chan PS, Ting HH, Gosch KL et al. Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. Journal of the American College of Cardiology. 2017;69(20):2475–84. DOI: 10.1016/j.jacc.2017.03.540

21. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021;23(10):1612–76. DOI: 10.1093/europace/euab065

22. Rosenman MB, Baker L, Jing Y, Makenbaeva D, Meissner B, Simon TA et al. Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. Current Medical Research and Opinion. 2012;28(9):1407–14. DOI: 10.1185/03007995.2012.708653

23. Bassand J-P, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F et al. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Advances. 2021;5(4):1081–91. DOI: 10.1182/bloodadvances.2020003560

24. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM et al. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. Journal of the American College of Cardiology. 2014;63(20):2141–7. DOI: 10.1016/j.jacc.2014.02.549

25. Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. European Heart Journal. 2014;35(28):1873–80. DOI: 10.1093/eurheartj/ehu083

26. Majeed A, Hwang H-G, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L et al. Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. Circulation. 2013;128(21):2325–32. DOI: 10.1161/CIRCULATIONAHA.113.002332

27. Kawabori M, Niiya Y, Iwasaki M, Mabuchi S, Ozaki H, Matsubara K et al. Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants: Comparison with Warfarin. Journal of Stroke and Cerebrovascular Diseases. 2018;27(5):1338–42. DOI: 10.1016/j.jstrokecerebrovasdis.2017.12.020

28. Beyer-Westendorf J, Förster K, Pannach S, Ebertz F, Gelbricht V, Thieme C et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955–62. DOI: 10.1182/blood-2014-03-563577

29. Friberg L, Rosenqvist M, Lip GYH. Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study. Circulation. 2012;125(19):2298–307. DOI: 10.1161/CIRCULATIONAHA.111.055079

30. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2020;76(5):594–622. DOI: 10.1016/j.jacc.2020.04.053

31. Министерство Здравоохранения Российской Федерации. Клинические рекомендации: Фибрилляция и трепетание предсердий у взрослых. (КР382). 2020. Доступно на: https://cr.minzdrav.gov.ru/recomend/382_1

32. Pfeilschifter W, Luger S, Brunkhorst R, Lindhoff-Last E, Foerch C. The Gap between Trial Data and Clinical Practice An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation. Cerebrovascular Diseases. 2013;36(2):115–9. DOI: 10.1159/000352062

33. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. Journal of the American College of Cardiology. 2017;69(23):2779–90. DOI: 10.1016/j.jacc.2017.03.600

34. Steffel J, Hindricks G. Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis. European Heart Journal. 2012;33(22):2766–8. DOI: 10.1093/eurheartj/ehs267

35. Лукьянов М.М., Бойцов С.А., Якушин C.C., Марцевич С.Ю., Воробьев А.Н., Загребельный А.В. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным регистра кардиоваскулярных заболеваний РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии. 2014;10(4):366-77. DOI: 10.20996/1819-6446-2014-10-4-366-377

36. Fox KAA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal. 2011;32(19):2387–94. DOI: 10.1093/eurheartj/ehr342

37. Чашкина М.И., Андреев Д.А., Козловская Н.Л., Салпагарова З.К., Суворов А.Ю., Сучкова С.А. и др. Показатели безопасности ривароксабана по сравнению с варфарином у пациентов с фибрилляцией предсердий и хронической болезнью почек поздних стадий. Кардиология. 2020;60(11):94–100. DOI: 10.18087/cardio.2020.11.n1322

38. Bansal N, Zelnick LR, Alonso A, Benjamin EJ, de Boer IH, Deo R et al. eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clinical Journal of the American Society of Nephrology. 2017;12(9):1386– 98. DOI: 10.2215/CJN.01860217

39. Yao X, Tangri N, Gersh BJ, Sangaralingham LR, Shah ND, Nath KA et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2017;70(21):2621–32. DOI: 10.1016/j.jacc.2017.09.1087

40. Lauschke V, Ingelman-Sundberg M. The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. International Journal of Molecular Sciences. 2016;17(10):1714. DOI: 10.3390/ijms17101714

41. Wang C, Wu VC, Kuo C, Chu P, Tseng H, Wen M et al. Efficacy and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study. Journal of the American Heart Association. 2018;7(15):e009263. DOI: 10.1161/JAHA.118.009263

42. Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Büller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood. 2008;111(9):4471–6. DOI: 10.1182/blood-2007-11-123711

43. Эрлих А.Д., Ткаченко К.Г., Утёмов А.А. Особенности использования оральных антикоагулянтов у пациентов с острым коронарным синдромом и фибрилляцией предсердий в реальной клинической практике (по данным регистра РЕКОРД). Лечебное дело. 2017;1:51-6

44. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883–91. DOI: 10.1056/NEJMoa1009638

45. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981–92. DOI: 10.1056/NEJMoa1107039

46. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361(12):1139–51. DOI: 10.1056/NEJMoa0905561

47. Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh E-Y et al. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin. Journal of the American College of Cardiology. 2015;66(21):2271–81. DOI: 10.1016/j.jacc.2015.09.024

48. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. The Lancet. 2012;380(9855):1749–58. DOI: 10.1016/S0140-6736(12)60986-6

49. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR et al. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138–46. DOI: 10.1161/CIRCULATIONAHA.113.005008

50. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. European Heart Journal. 2014;35(28):1864–72. DOI: 10.1093/eurheartj/ehu046

51. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation Clinical Perspective: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Circulation. 2011;123(21):2363–72. DOI: 10.1161/CIRCULATIONAHA.110.004747

52. Hanon O, Vidal J-S, Pisica-Donose G, Orvoën G, David J-P, Chaussade E et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2021;107(17):1376–82. DOI: 10.1136/heartjnl-2020-317923

53. Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):e001592. DOI: 10.1136/bmjopen2012-001592

54. Loke YK, Pradhan S, Yeong JK, Kwok CS. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. British Journal of Clinical Pharmacology. 2014;78(4):707–17. DOI: 10.1111/bcp.12376

55. Chatterjee S, Sharma A, Uchino K, Biondi-Zoccai G, Lichstein E, Mukherjee D. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coronary Artery Disease. 2013;24(8):628–35. DOI: 10.1097/MCA.0000000000000031

56. Benedetti G, Neccia M, Agati L. Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence. Minerva Cardioangiologica. 2018;66(3):301–13. DOI: 10.23736/S0026-4725.17.04553-4

57. Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):149-218. DOI: 10.15829/1560-4071-2020-3-3786

58. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018;36(10):1953– 2041. DOI: 10.1097/HJH.0000000000001940

59. Bhangu J, King-Kallimanis BL, Donoghue OA, Carroll L, Kenny RA. Falls, non-accidental falls and syncope in community-dwelling adults aged 50 years and older: Implications for cardiovascular assessment. PLOS ONE. 2017;12(7):e0180997. DOI: 10.1371/journal.pone.0180997

60. Hylek EM, D’Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation. Stroke. 2006;37(4):1075–80. DOI: 10.1161/01.STR.0000209239.71702.ce

61. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Archives of Internal Medicine. 1999;159(7):677–85. DOI: 10.1001/archinte.159.7.677

62. Tiedemann A, Lord SR, Sherrington C. The Development and Validation of a Brief Performance-Based Fall Risk Assessment Tool for Use in Primary Care. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2010;65(8):896–903. DOI: 10.1093/gerona/glq067

63. Camm AJ, Cools F, Virdone S, Bassand J-P, Fitzmaurice DA, Arthur Fox KA et al. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. Journal of the American College of Cardiology. 2020;76(12):1425–36. DOI: 10.1016/j.jacc.2020.07.045

64. Качковский М.А., Краснослободская О.В. Приверженность медикаментозной терапии больных с фибрилляцией предсердий. Вестник Российского университета дружбы народов. Серия: Медицина. 2010;4:229-33.

65. Kozieł M, Mazurek M, Teutsch C, Diener H-C, Dubner SJ, Halperin JL et al. Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. Journal of Clinical Medicine. 2020;9(6):1969. DOI: 10.3390/jcm9061969

66. Туров А.Н., Панфилов С.В., Чиглинцева О.В. Эффективность, безопасность и приверженность при использовании новых антикоагулянтов у пациентов с фибрилляцией предсердий старше 75 лет. Рациональная Фармакотерапия в Кардиологии. 2020;16(1):10-8. DOI: 10.20996/1819-6446-2020-20-07


Рецензия

Для цитирования:


Беленков Ю.Н., Попова Л.В., Ильгисонис И.С. Тактика ведения пациентов с фибрилляцией предсердий и малыми кровотечениями в условиях терапии прямыми пероральными антикоагулянтами. Кардиология. 2021;61(12):72-81. https://doi.org/10.18087/cardio.2021.12.n1872

For citation:


Belenkov Yu.N., Popova L.V., Ilgisonis S.I. Management of patients with atrial fibrillation and minor bleeding during therapy with direct oral anti-coagulants. Kardiologiia. 2021;61(12):72-81. (In Russ.) https://doi.org/10.18087/cardio.2021.12.n1872

Просмотров: 371


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)